oseltamivir phosphate

FDA Drug Profile — OSELTAMIVIR PHOSPHATE, oseltamivir phosphate, Oseltamivir Phosphate, Oseltamivir phosphate, Tamiflu

oseltamivir phosphate is listed in the FDA National Drug Code directory with 39 NDC codes, marketed under brand names including OSELTAMIVIR PHOSPHATE, oseltamivir phosphate, Oseltamivir Phosphate. Available dosage forms: for suspension, capsule, suspension, powder, for suspension, powder.

Drug details

Generic Name
oseltamivir phosphate
Brand Names
OSELTAMIVIR PHOSPHATE, oseltamivir phosphate, Oseltamivir Phosphate, Oseltamivir phosphate, Tamiflu
Application Number
ANDA209113
Sponsor
Zydus Pharmaceuticals USA Inc.
NDC Codes
39
Dosage Forms
FOR SUSPENSION, CAPSULE, SUSPENSION, POWDER, FOR SUSPENSION, POWDER
Routes
ORAL
Active Ingredients
OSELTAMIVIR PHOSPHATE

Indications and Usage

1 INDICATIONS AND USAGE Oseltamivir Phosphate capsule is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir Phosphate capsule is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir Phosphate capsule is indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use Oseltamivir Phosphate capsule is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Oseltamivir Phosphate Capsule [see Microbiology (12.4)]. Oseltamivir Phosphate capsule is not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration (2.4) and Use in Specific Populations (8.6)].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.